Search results
Elimination – metabolites excreted renally (95%) and in faeces (4%); context-sensitive half-life varies from 4 min for a 10 min infusion to 250 min for an 8 h infusion; EVIDENCE
19 sty 2017 · Preterm neonates had lower weight-adjusted plasma clearance (0.3 vs. 0.9 L/h/kg) and an increased elimination half-life (7.6 vs. 3.2 h) than term neonates. Premature neonates were adequately sedated with dexmedetomidine alone, although doses up to 0.2 µg/kg/h were not sufficient in most term neonates.
The terminal elimination half-life (t 1/2) of dexmedetomidine is approximately 2 hours and clearance is estimated to be approximately 39 L/h. A mass balance study demonstrated that after nine days an average of 95% of the radioactivity, following intravenous administration of radiolabeled dexmedetomidine, was recovered in the urine and 4% in ...
17 lut 2020 · Last updated January 15, 2020. Includes Dexmedetomidine indications, dosage/administration, pharmacology, mechanism/onset/duration of action, half-life, dosage forms, interactions, warnings, adverse reactions, off-label uses and more.
Half-life. 2 hours. Clearance. 39 L/h [Healthy volunteers receiving IV infusion (0.2-0.7 mcg/kg/hr)] Adverse Effects
The terminal elimination half-life of intravenous dexmedetomidine ranged 2.1 to 3.1 hours in healthy adults and 2.2 to 3.7 hours in ICU patients. [7] The plasma protein binding of dexmedetomidine is about 94% (mostly albumin). [4]
1 maj 2023 · Objectives: Identify the mechanism of action of dexmedetomidine. Summarize the indicated uses for dexmedetomidine. Review the adverse effect profile and contraindications of dexmedetomidine.
